GlassScriptPhysician profile
Barton G Sickinger
NPI 1245223650
$11,405.07
in general payments reported to CMS, 2019-2025
47 companies · $2,219 in 2025
The $2,219 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,888 · 2020: $1,628 · 2021: $2,345 · 2022: $1,407 · 2023: $829 · 2024: $1,089 · 2025: $2,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,137.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,314.58 | 2019-2024 | Xarelto |
| Aop Health US, LLC | $1,154.90 | 2025 | Rapiblyk |
| Abbott Laboratories | $1,144.47 | 2019-2024 | Amplatzer Amulet, Amplatzer Talisman, Cardiomems |
| Amarin Pharma, INC. | $807.51 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $729.77 | 2019-2025 | Jardiance |
| Cvrx, INC. | $606.54 | 2020-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $583.13 | 2021-2025 | Verquvo, Capvaxive |
| Astellas Pharma US INC | $525.49 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $477.26 | 2019-2023 | |
| Pfizer INC. | $446.33 | 2019-2025 | |
| Esperion Therapeutics, INC. | $419.02 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $355.27 | 2019-2025 | |
| Amgen INC. | $347.76 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $242.51 | 2019-2025 | Farxiga, Andexxa |
| Atricure, INC. | $201.12 | 2022-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax, Epi-Ease Epicardial Access System |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barton Sickinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.